Killer App for Vaccines: Baculovirus Expression

Mar 16, 2013

Genetic Engineering & Biotechnology News

Protein Sciences’ Flublok won the Food and Drug Administration’s approval in January thus introducing the world to the first recombinant trivalent hemagglutinin (rHA) influenza vaccine, based on a baculovirus expression system. This expression technology is fast becoming the killer app when it comes to producing vaccines efficiently and cost effectively. Genetic Engineering @ Biotechnology News correspondent Lina Genovesi highlights its successes in her report on the baculovirus expression technology track at the ISBiotech conference recently held in Arlington, Va.

Read the full story here

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments